Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Wellbutrin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bupropion HCl 100 mg Tablets (Invamed Inc.) |
| 2 | ACTIVE_COMPARATOR | Wellbutrin 100 mg Tablets (Glaxo Wellcome) |
| Name | Type | Description |
|---|---|---|
| Bupropion HCl 100 mg Tablets (Invamed Inc.) | DRUG | - |
| Wellbutrin 100 mg Tablets (Glaxo Wellcome) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Wellbutrin is an investigational small molecule being studied in healthy volunteers. It is being developed by Novartis AG. The drug is currently in Phase 1 clinical development, with one completed trial evaluating its relative bioavailability under fasting conditions.
Wellbutrin is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Wellbutrin is in Phase 1 clinical development. It has one completed Phase 1 trial, NCT00883155, which evaluated the relative bioavailability of bupropion HCl 100 mg tablets under fasting conditions in 36 healthy male volunteers. The drug is not yet approved and remains investigational.
Wellbutrin has one completed clinical trial, NCT00883155, titled 'To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions.' This Phase 1 study enrolled 36 healthy male volunteers aged 18 years and older and was active-controlled.
Wellbutrin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only completed trial, NCT00883155, was a bioavailability study in healthy volunteers, and the drug has not yet progressed to later-stage trials or regulatory approval.